SCHEMBL17985018

SCHEMBL17985018

NC(=O)c1ccc2c(n1)CCN(Cc1ccccc1)C2

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.56
MEN1 O00255 3/20 0.56
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
DHFR P00374 1/20 0.53
TP53 P04637 5/20 0.53
MAPT P10636 5/20 0.53
OPRM1 P35372 2/20 0.49
OPRD1 P41143 2/20 0.49
OPRK1 P41145 2/20 0.49
SMN1; SMN2 Q16637 4/20 0.48
POLB P06746 1/20 0.47
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
MAPK1 P28482 1/20 0.46
GRM2 Q14416 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL721096 0.91 KMT2A (0.57) KMT2AMEN1NPC1RAB9ADHFR
SCHEMBL17984862 0.89 MEN1 (0.55) KMT2AMEN1NPC1RAB9ADHFR
SCHEMBL16264685 0.89 KMT2A (0.55) KMT2AMEN1NPC1RAB9ADHFR
SCHEMBL10224092 0.86 RAB9A (0.53) KMT2AMEN1NPC1RAB9ADHFR
SCHEMBL10209789 0.85 NPC1 (0.52) KMT2AMEN1NPC1RAB9ADHFR
Hydrochloric Acid SCHEMBL720333 0.84 NPC1 (0.51) KMT2AMEN1NPC1RAB9ADHFR
SCHEMBL19664789 0.84 KMT2A (0.51) KMT2AMEN1NPC1RAB9ADHFR
SCHEMBL19664788 0.84 KMT2A (0.51) KMT2AMEN1NPC1RAB9ADHFR
SCHEMBL19674797 0.82 NPC1 (0.48) KMT2AMEN1NPC1RAB9ADHFR
SCHEMBL30474239 0.81 KMT2A (0.61) KMT2AMEN1NPC1RAB9ADHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107207532-B Nitroimidazole derivatives against tuberculosis 南京明德新药研发股份有限公司 2019-07-30 CN disclosed
US-10227362-B2 Anti-pulmonary tuberculosis nitroimidazole derivative MEDSHINE DISCOVERY INC. (CN) 2019-03-12 US disclosed
US-10227362-B2 Anti-pulmonary tuberculosis nitroimidazole derivative MEDSHINE DISCOVERY INC. (CN) 2019-03-12 US disclosed
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE MEDSHINE DISCOVERY INC. (CN) 2018-06-14 US disclosed
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE MEDSHINE DISCOVERY INC. (CN) 2018-06-14 US disclosed
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE MEDSHINE DISCOVERY INC. (CN) 2018-06-14 US disclosed
EP-3252059-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE Medshine Discovery Inc. (CN) 2017-12-06 EP disclosed
EP-3252059-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE Medshine Discovery Inc. (CN) 2017-12-06 EP disclosed
CN-107207532-A Nitroimidazole derivatives against tuberculosis 南京明德新药研发股份有限公司 2017-09-26 CN disclosed
WO-2016119706-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE 南京明德新药研发股份有限公司 2016-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE NDUFV1, NDUFV2, MT-ND4 KMT2A 3039/4885MEN1 4332/4885NPC1 1571/4885
US-10227362-B2 Anti-pulmonary tuberculosis nitroimidazole derivative NDUFV1, NDUFV2, MT-ND4 KMT2A 3039/4885MEN1 4332/4885NPC1 1571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.